Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Prozac For Premenstrual Dysphoric Disorder May Get "Fem"-inine Touch

  • News

Executive Summary

Lilly is planning to market its blockbuster antidepressant Prozac (fluoxetine) with separate packaging and a new name for treatment of premenstrual dysphoric disorder.

You may also be interested in...



Lilly Sarafem PMDD Therapy Approved With Patient Package Insert

Lilly's pre-menstrual dysphoric disorder packaging for fluoxetine (Sarafem) will include a patient package insert.

Lilly Sarafem PMDD Therapy Approved With Patient Package Insert

Lilly's pre-menstrual dysphoric disorder packaging for fluoxetine (Sarafem) will include a patient package insert.

Lilly Fluoxetine For Premenstrual Dysphoria Merits Separate Indication

Labeling for Lilly's fluoxetine (Prozac) should include a separate indication for premenstrual dysphoric disorder, FDA's Psychopharmacologic Drugs Advisory Committee agreed Nov. 3.

Table

View full table

Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS035147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By